STAAR Surgical Posts Strong Q2 2026 Results on China Growth
Event summary
- STAAR Surgical reported Q2 2026 net sales of $93.5 million, up 111% year-over-year.
- China sales surged over 100%, representing more than 50% of total revenue.
- Net income turned positive at $8.1 million, compared to a loss of $(16.8) million in Q2 2025.
- Gross margin improved slightly to 74.5% from 74.0% year-over-year.
- Warren Foust assumed the role of CEO, succeeding Deborah Andrews as CFO.
The big picture
STAAR Surgical's strong Q2 2026 results highlight its growing dominance in the Chinese refractive surgery market, where lens-based procedures are gaining traction over laser alternatives. The company's strategic focus on profit expansion and innovation acceleration positions it well to capitalize on the global rise of myopia, though execution risks remain as it scales operations and invests in new technologies.
What we're watching
- Market Share Dynamics
- How STAAR can sustain its market share gains in China against laser-based procedures.
- Execution Risk
- The pace at which STAAR can integrate new ERP systems and scale production efficiency.
- Innovation Pipeline
- Whether the company's R&D investments will yield next-generation products to maintain growth momentum.
Related topics